|Bid||40.94 x 800|
|Ask||40.95 x 1400|
|Day's range||38.16 - 41.29|
|52-week range||34.88 - 277.80|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.
This year hasn't been an easy one for Novavax (NASDAQ: NVAX) investors. After a series of stumbles culminating in its disastrous earnings report on Aug. 8, its shares are down by 60% so far in 2022. And with management slashing its full-year revenue guidance by roughly half, there isn't much hope for smoother sailing for at least a few quarters.
A more than 30% peak decline in the Nasdaq Composite is allowing investors to buy these phenomenal stocks at bargain-basement prices.